Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases.

导出 LinkOut

翻译打印收藏纠错

作者： Sinead,O'Sullivan ^[1] ; Kumlesh K,Dev ^[2]

作者单位： Drug Development, School of Medicine, Trinity College Dublin, Ireland. ^[1] Drug Development, School of Medicine, Trinity College Dublin, Ireland. Electronic address: devk@tcd.ie. ^[2]

关键词 Ceralifimod (PubChem CID: 11502996)Clinical trials FTY720 Fingolimod Fingolimod (PubChem CID: 107970)Ozanimod (PubChem CID: 52938427)Ponesimod (PubChem CID: 11363176)Siponimod (PubChem CID: 44599207)Sphingosine1-phosphate receptors (S1PRs)

主题词动物(Animals);中枢神经系统药物(Central Nervous System Agents);中枢神经系统疾病(Central Nervous System Diseases);临床试验(主题)(Clinical Trials as Topic);人类(Humans);溶血磷脂素类(Lysophospholipids);受体, 鞘磷脂(Receptors, Lysosphingolipid);鞘氨醇(Sphingosine)

DOI 10.1016/j.neuropharm.2016.11.006

PMID 27825807

发布时间 2017-05-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览36

Neuropharmacology

2017年113卷Pt B期

597-607页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases.

Neuropharmacology

相似文献

Neuropharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases.

Neuropharmacology

相似文献

Neuropharmacology

相关期刊

检索历史清除